Mechanisms of the cardioprotective effect of lithium
A. V. Mukhomedzyanov,
E. V. Plotnikov,
L. N. Maslov,
V. I. Chernov,
N. V. Naryzhnaya,
A. S. Slidnevskaya,
M. S. Yusubov,
M. S. Larkina,
A. A. Artamonov,
M. V. Belousov https://doi.org/10.20538/1682-0363-2025-1-52-59
Abstract
Background. A study of the mechanisms of infarct size-limiting effects of lithium chloride (LiCl) on a model of myocardial infarction in vivo. Myocardial infarction is one of the main causes of death among the adult working population in economically developed countries. Currently, there are no drugs in clinical practice that would effectively protect the myocardium against ischemia – reperfusion injury, so there is a need to develop new drugs that can limit infarct size and reduce mortality.
Aim. To study the mechanisms of infarct size-limiting effects of lithium chloride.
Materials and methods. A study was performed in anesthetized Wistar rats with coronary artery occlusion (45 min) and reperfusion (120 min). The molecular mechanism of the protective effects of LiCl was examined in this model using appropriate blockers, including non-selective and selective blockers of ATP-sensitive potassium channel and NO synthase.
Results. Administration of LiCl before ischemia significantly reduced infarct size as well as the as the incidence of ventricular arrhythmias. Administration of LiCl after ischemia also promoted a decrease in infarct size. NO synthase, cycloxigenase-2, protein kinase C, and endogenous opioids were not involved in the cardioprotective effect of lithium. The cardioprotective effect of LiCl is mediated via sarcolemmal ATP-sensitive potassium channel (sarcKATP channel) opening.
Conclusion. LiCl reduced infarct size and prevented reperfusion cardiac injury. The main cellular ways of the infarct size-limiting effects of LiCl are mediated through the sarcKATP channel opening.
Supporting agencies: Priority 2030 Program.
About the Authors
A. V. Mukhomedzyanov
Cardiology Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
111a, Kievskaya Str., Tomsk, 634012
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article.
E. V. Plotnikov
National Research Tomsk Polytechnic University (NR TPU);
Siberian State Medical University;
Mental Health Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
30, Lenina Av., Tomsk. 634050;
2, Moscow Trakt, Tomsk, 634050;
4, Aleutskaya Str., Tomsk, 634021
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article.
L. N. Maslov
Cardiology Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
111a, Kievskaya Str., Tomsk, 634012
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article.
V. I. Chernov
National Research Tomsk Polytechnic University (NR TPU);
Cancer Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
30, Lenina Av., Tomsk. 634050;
5, Kooperativny Str., Tomsk, 634009
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article.
N. V. Naryzhnaya
Cardiology Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
111a, Kievskaya Str., Tomsk, 634012
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article.
A. S. Slidnevskaya
Cardiology Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
111a, Kievskaya Str., Tomsk, 634012
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article.
M. S. Yusubov
National Research Tomsk Polytechnic University (NR TPU)
Russian Federation
Competing Interests:
Russian Federation
30, Lenina Av., Tomsk. 634050
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article.
M. S. Larkina
National Research Tomsk Polytechnic University (NR TPU);
Siberian State Medical University
Russian Federation
Competing Interests:
Russian Federation
30, Lenina Av., Tomsk. 634050;
2, Moscow Trakt, Tomsk, 634050
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article.
A. A. Artamonov
Institute of Biomedical Problems, Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
76а, Khoroshevskoe Highway, Moscow, 123007
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article.
M. V. Belousov
National Research Tomsk Polytechnic University (NR TPU);
Siberian State Medical University
Russian Federation
Competing Interests:
Russian Federation
30, Lenina Av., Tomsk. 634050;
2, Moscow Trakt, Tomsk, 634050
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article.
References
1. Pearson-Stuttard J., Bennett J., Cheng Y.J., Vamos E.P., Cross A.J., Ezzati M. et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol. 2021;9(3):165–173. DOI: 10.1016/S2213-8587(20)30431-9.
2. Shen L., Xian Y., Chen A.Y., Thomas L., Roe M.T., Peterson E.D. et al. Effect of intervention timing on one-year mortality in elderly non-ST-segment elevation myocardial infarction patients. Coron. Artery Dis. 2021;32(2):138–144. DOI: 10.1097/MCA.0000000000000916.
3. Yaqoub L., Gad M., Saad A.M., Elgendy I.Y., Mahmoud A.N. National trends of utilization and readmission rates with intravascular ultrasound use for ST-elevation myocardial infarction. Catheter Cardiovasc. Interv. 2021;98(1):1–9. DOI: 10.1002/ccd.29524.
4. Ullah W., Saleem S., Zahid S., Sattar Y., Mukhtar M., Younas S. et al. Clinical outcomes of patients with diabetes mellitus and acute ST-elevation myocardial infarction following fibrinolytic therapy: a nationwide inpatient sample (NIS) database analysis. Expert Rev. Cardiovasc. Ther. 2021;19(4):357–362. DOI: 10.1080/14779072.2021.1888716.
5. Singh S.K., Witer L., Kaku Y., Masoumi A., Fried J.A., Yuzefpolskaya M. et al. Temporary surgical ventricular assist device for treatment of acute myocardial infarction and refractory cardiogenic shock in the percutaneous device era. J. Artif. Organs. 2021;24(2):199–206. DOI: 10.1007/s10047-020-01236-2.
6. Hinton J., Mariathas M., Gabara L., Nicholas Z., Allan R., Ramamoorthy S. et al. Distribution of contemporary sensitivity troponin in the emergency department and relationship to 30-day mortality: The CHARIOT-ED sub study. Clin. Med. 2020;20(6):528–534. DOI: 10.7861/clinmed.2020-0267.
7. Arora S., Cavender M.A., Chang P.P., Qamar A., Rosamond W.D., Hall M.E. et al. Outcomes of decreasing versus increasing cardiac troponin in patients admitted with non-STsegment elevation myocardial infarction: the Atherosclerosis Risk in Communities Surveillance Study. Eur. Heart J. Acute Cardiovasc. Care. 20216;10(9):1048–1055. DOI: 10.1093/ehjacc/zuaa051.
8. Roolvink V., Ibáñez B., Ottervanger J.P., Pizarro G., van Royen N., Mateos A. et al. EARLY-BAMI investigators. Early intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention. J. Am. Coll. Cardiol. 2016;67(23):2705–2715. DOI: 10.1016/j.jacc.2016.03.522.
9. Plotnikov E., Korotkova E., Voronova O. Lithium salts of Krebs cycle substrates as potential normothymic antioxidant agents. J. Pharm. Bioall. Sci. 2018;10(4):240–245. DOI: 10.4103/JPBS.JPBS_140_18.
10. Wang W., Lu D., Shi Y., Wang Y. Exploring the Neuroprotective Effects of Lithium in Ischemic Stroke: A literature review. Int. J. Med. Sci. 2024;21(2):284–298. DOI: 10.7150/ijms.88195.
11. Plotnikov E., Voronova O., Linert W., Martemianov D., Korotkova E., Dorozhko E. et al. Antioxidant and immunotropic properties of some lithium salts. J. App. Pharm. Sci. 2016;6(1):086–089. DOI: 10.7324/JAPS.2016.600115.
12. Terashima Y., Sato T., Yano T., Maas O., Itoh T., Miki T. et al. Roles of phospho-GSK-3β in myocardial protection afforded by activation of the mitochondrial K ATP channel. J. Mol. Cell Cardiol. 2010;49(5):762–770. DOI: 10.1016/j.yjmcc.2010.08.001.
13. Faghihi M., Mirershadi F., Dehpour A.R., Bazargan M. Preconditioning with acute and chronic lithium administration reduces ischemia/reperfusion injury mediated by cyclooxygenase not nitric oxide synthase pathway in isolated rat heart. Eur. J. Pharmacol. 2008;597(1-3):57–63. DOI: 10.1016/j.ejphar.2008.08.010.
14. Banafshe H.R., Mesdaghinia A., Arani M.N., Ramezani M.H., Heydari A., Hamidi G.A. Lithium attenuates pain-related behavior in a rat model of neuropathic pain: possible involvement of opioid system. Pharmacol. Biochem. Behav. 2012;100(3):425–430. DOI: 10.1016/j.pbb.2011.10.004.
15. Abdel-Zaher A.O., Abdel-Rahman M.M. Lithium chloride-induced cardiovascular changes in rabbits are mediated by adenosine triphosphate-sensitive potassium channels. Pharmacol. Res. 1999;39(4):275–282. DOI: 10.1006/phrs.1998.0445.
16. Yellon D.M., Downey J.M. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol. Rev. 2003;83(4):1113–1151. DOI: 10.1152/physrev.00009.2003.
17. Heusch G. Myocardial ischaemia-reperfusion injury and cardioprotection in perspective. Nat. Rev. Cardiol. 2020;17(12):773–789. DOI: 10.1038/s41569-020-0403-y.
18. Ebrahim Z., Yellon D.M., Baxter G.F. Bradykinin elicits “second window” myocardial protection in rat heart through an NO-dependent mechanism. Am. J. Physiol. Heart Circ. Physiol. 2001;281(3):H1458–1464. DOI: 10.1152/ajpheart.2001.281.3.H1458.
19. Zhao J., Su Y., Zhang Y., Pan Z., Yang L., Chen X. et al. Activation of cardiac muscarinic M3 receptors induces delayed cardioprotection by preserving phosphorylated connexin43 and up-regulating cyclooxygenase-2 expression. Br. J. Pharmacol. 2010;159(6):1217–1225. DOI: 10.1111/j.1476-5381.2009.00606.x.
20. Hausenloy D.J., Yellon D.M. The second window of preconditioning (SWOP) where are we now? Cardiovasc. Drugs Ther. 2010;24(3):235–254. DOI: 10.1007/s10557-010-6237-9.
21. Percie du Sert N., Hurst V., Ahluwalia A. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 2020;18(7):e3000410. DOI: 10.1371/journal.pbio.3000410.
22. Neckár J., Papousek F., Nováková O., Ost’ádal B., Kolár F. Cardioprotective effects of chronic hypoxia and ischaemic preconditioning are not additive. Basic Res. Cardiol. 2002;97(2):161–167. DOI: 10.1007/s003950200007.
23. Stevens A.M., Liu L., Bertovich D., Janjic J.M., Pollock J.A. Differential expression of neuroinflammatory mRNAs in the rat sciatic nerve following chronic constriction injury and pain-relieving nanoemulsion NSAID delivery to infiltrating macrophages. Int. J. Mol. Sci. 2019;20(21):5269. DOI: 10.3390/ijms20215269.
24. Kwak H.J., Park K.M., Choi H.E., Park H.Y. Protective mechanisms of NO preconditioning against NO-induced apoptosis in H9c2 cells: role of PKC and COX-2. Free Radic. Res. 2009;43(8):744–752. DOI: 10.1080/10715760903040602.
25. Maslov L.N., Khaliulin I., Oeltgen P.R., Naryzhnaya N.V., Pei J.M., Brown S.A. et al. Prospects for creation of cardioprotective and antiarrhythmic drugs based on opioid receptor agonists. Med. Res. Rev. 2016;36(5):871–923. DOI: 10.1002/med.21395.
26. Fountoulakis K.N., Tohen M., Zarate C.A. Jr. Lithium treatment of Bipolar disorder in adults: A systematic review of randomized trials and meta-analyses. Eur. Neuropsychopharmacol. 2022;54:100–115. DOI: 10.1016/j.euroneuro.2021.10.003.
Review
For citations:
Mukhomedzyanov A.V., Plotnikov E.V., Maslov L.N., Chernov V.I., Naryzhnaya N.V., Slidnevskaya A.S., Yusubov M.S., Larkina M.S., Artamonov A.A., Belousov M.V. Mechanisms of the cardioprotective effect of lithium. Bulletin of Siberian Medicine. 2025;24(1):52-59. https://doi.org/10.20538/1682-0363-2025-1-52-59
Views:
271
Email this article 